Premium
Aberrant deleted in liver cancer‐1 expression is associated with tumor metastasis and poor prognosis in urothelial carcinoma
Author(s) -
Chen WanTzu,
Yang ChingHsiu,
Wu ChunChieh,
Huang YaChun,
Chai CheeYin
Publication year - 2013
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12060
Subject(s) - tissue microarray , immunohistochemistry , metastasis , medicine , cancer , biomarker , pathology , carcinoma , oncology , cancer research , biology , biochemistry
This study explored the potential role of deleted in liver cancer‐1 ( DLC ‐1) as a prognostic indicator of cancer metastasis and survival in urothelial carcinoma ( UC ). Tissue microarrays were constructed from paraffin‐embedded specimens from 88 UC patients, and immunohistochemical staining was performed to investigate the association of DLC ‐1 with clinicopathologic characteristics and clinical outcome. The DLC ‐1 expression showed a significant positive correlation with tumor location (p = 0.041) and a significant negative correlation with advanced histological grade (p = 0.013). In tumors with low DLC ‐1 expression, Bcl‐2 positivity was observed in 24.4% of cases. The DLC ‐1 expression had significant negative associations with Bcl‐2 expression (p = 0.032) and with highly metastatic UC (p = 0.032). Kaplan–Meier analysis showed that DLC ‐1 protein expression was negatively associated with both overall survival ( OS ) (p = 0.035) and with distant metastasis‐free survival ( DMFS ) (p = 0.041), but not with disease‐free survival. Multivariate analyses indicated that tumor size was the significant independent predictors of OS (p = 0.048); however, only DLC ‐1 expression was a significant independent predictor of DMFS (p = 0.019). In conclusion, reduced DLC ‐1 protein expression may be an important factor in tumor progression and a useful prognostic molecular marker in UC .